Form 4: ARS Pharmaceuticals Director Phillip M Schneider Acquires 40,000 Stock Options
SEC Form 4 Filing
Director Phillip M Schneider reports acquisition of 40,000 stock options in ARS Pharmaceuticals, Inc.
Summary
- On June 20, 2024, Phillip M Schneider, a director of ARS Pharmaceuticals, Inc. (SPRY), acquired 40,000 stock options.
- The options have an exercise price of $7.73.
- The options vest fully on the earlier of June 20, 2025, or the date of the Issuer's 2025 annual meeting of stockholders.
- The options expire on June 19, 2034.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of transaction: Phillip M Schneider acquired 40,000 stock options. |
| 06/20/2025 | Options vest fully on the earlier of this date or the date of the Issuer's 2025 annual meeting of stockholders. |
| 06/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.